Skip to NavigationSkip to content

New Zealand Government signs deal with Pfizer and BioNTech for 1.5 million COVID-19 vaccines

Published on 12/10/20 at 01:28pm
Photo by New Zealand Parliament

The New Zealand Government has signed a deal with Pfizer and BioNTech for one of their promising COVID-19 vaccine candidates. 

Like most countries, this is just one of several deals that New Zealand has agreed or is currently negotiating to cover all of its five million citizens. 

Megan Woods, the Government Research Minister, said: “The additional agreements will ensure that once the portfolio is completed, we will have sufficient COVID-19 vaccines for the whole population.” 

New Zealand has been held up as a global example of how to deal with COVID-19, as it has recorded 1,800 cases and only 25 deaths so far. 

The deal specifically relates to one of Pfizer-BioNTech mRNA vaccines known as BNT162b2, which is in large-scale Phase 3 trials. 

Last week, the European Medicines Agency announced it was speeding up its regulatory processes to allow quick approval for the BNT162b2 vaccine. The European Commission has said it will purchase 200 million doses from the companies with an option to buy an additional 100 million. 

The US has also secured deals for millions of doses, purchasing a supply of 100 million doses for $1.95 billion. 

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches